Cash from Investing (Quarterly) Chart

View Cash from Investing (Quarterly) for IRWD.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Investing (Quarterly) Chart
Start Trial

Historical Cash from Investing (Quarterly) Data

View and export this data back to 2009. Start Trial.
Date Value
June 30, 2026 0.00
March 31, 2026 0.00
December 31, 2025 0.001M
September 30, 2025 -0.002M
June 30, 2025 -0.002M
March 31, 2025 -0.031M
December 31, 2024 0.00
September 30, 2024 -0.016M
June 30, 2024 -0.058M
March 31, 2024 -0.068M
December 31, 2023 -4.188M
September 30, 2023 -22.62M
June 30, 2023 -999.49M
March 31, 2023 -0.013M
December 31, 2022 0.027M
September 30, 2022 -0.066M
June 30, 2022 -0.088M
March 31, 2022 -0.009M
December 31, 2021 -0.128M
September 30, 2021 -0.137M
June 30, 2021 0.00
March 31, 2021 0.00
December 31, 2020 -0.028M
September 30, 2020 0.00
June 30, 2020 -0.376M
Date Value
March 31, 2020 -1.438M
December 31, 2019 -2.661M
September 30, 2019 -3.077M
June 30, 2019 -2.429M
March 31, 2019 -2.977M
December 31, 2018 17.49M
September 30, 2018 14.28M
June 30, 2018 12.44M
March 31, 2018 44.65M
December 31, 2017 -33.85M
September 30, 2017 26.66M
June 30, 2017 70.60M
March 31, 2017 88.06M
December 31, 2016 -115.42M
September 30, 2016 -90.36M
June 30, 2016 4.763M
March 31, 2016 23.35M
December 31, 2015 34.91M
September 30, 2015 21.83M
June 30, 2015 -85.66M
March 31, 2015 19.76M
December 31, 2014 38.31M
September 30, 2014 -7.883M
June 30, 2014 -80.52M
March 31, 2014 -6.472M

Cash From Investing Definition

Represents the net cash flow from the company's investing activities. Investing activities represent the movement in the company's long-term assets.

Read full definition.

Cash from Investing (Quarterly) Range, Past 5 Years

View Cash from Investing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Investing (Quarterly) Benchmarks

View Cash from Investing (Quarterly) Benchmarks
Start Trial
Rigel Pharmaceuticals, Inc. 17.45M
AbbVie, Inc. -1.197B
Marker Therapeutics, Inc. 0.00
Theriva Biologics, Inc. -0.003M
Fortress Biotech, Inc. -0.079M